微信直播

AME专访|Tomoyuki Hishida: Surgical outcome of thymic carcinoma

Published at: 2015年第1卷第S1期

叶露娇
关键词:

编者按:第 6 届国际胸腺肿瘤协会年会(ITMIG 2015)于 2015 年 10 月 23-25 日在中国上海环球富豪东亚酒店成功举办。许多世界胸腺肿瘤领域著名的研究学者和临床专家参加了本次大会,报告了胸腺及其他纵隔肿瘤最新的基础和临床研究进展。来自日本 National Cancer Center Hospital East 的胸外科专家 Dr. Tomoyuki Hishida 在会议上就“Surgical outcome of thymic carcinoma”一题作了精彩报告。会后,小编荣幸地邀请到 Dr. Hishida 接受我们的专访。

采访问题

  1. Dr. Hishida, welcome to ITMIG 2015 and welcome to China. First of all, would you kindly introduce to us the current incidence of thymic carcinoma in Japan?

  2. As you are an expert in surgery for thymic carcinoma, what is the secret for a successful procedure?

  3. Would you kindly introduce to us the factors affecting survival after surgical treatment for thymic carcinoma?

  4. Minimally invasive surgery is a trend now, like Robotic surgery and VAST surgery. What is the current status of these surgeries for thymic carcinoma in your hospital?

  5. In your presentation, you talked about “Surgical outcome of thymic carcinoma”. Would you kindly summarize the key points of your presentation?

专家介绍

Dr. Tomoyuki Hishida, a thoracic surgeon at National Cancer Center Hospital East, Japan. Dr. Hishida received his M.D. and Ph. D at Nagoya University.

采访编辑|叶露娇,科学编辑,AME出版社。

视频剪辑|麦雪芳,视频编辑,AME出版社。

ITMIG 2015 专题

一年一度的购(duo)物(shou)节即将来临,你是否早早将心仪已久的好书揽入购物车,摩拳擦掌仍怕手慢?不怕,AME微店福利来了,何必等到双十一,错开高峰提前购。点击链接有惊喜,赶紧来领取吧!http://huodong.weidian.com/juan/get.html?wfr=shop_coupon_share&coupon_id=745926&shop_id=260520116&from=timeline&isappinstalled=0

doi:

10.3978/kysj.2014.1.1295
comments powered by Disqus

附件